CV Lattes
ResearcherID
ORCID
Secretaria da Saúde (São Paulo - Estado). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Associate Professor Level III, Department of Cardiopneumology, Faculty of Medicine, University of São Paulo (FMUSP). Representative of Associate Professors at the University Council of USP until August 2022. Director of the Clinical Unit of Interdisciplinary Medicine in Cardiology of the Heart Institute (UnMic) of the Hospital das Clínicas of FMUSP. President of the Department of Clinical Cardiology of the Brazilian Society of Cardiology, Coordinator of the Graduate Program in Medical Sciences of FMUSP, Fellow of the European Society of Cardiology through the Scientific Excellence category. Member of the Technical Board advising on Pharmacovigilance of Vaccines and other Immunobiologicals (CIFAVI) of the National Immunization Program of the Ministry of Health; Full member of the Research Committee of FMUSP since March 2013. Editor in Chief of the Journal of the Brazilian Medical Association from 2006 to 2013, Associate Editor of Plos One Magazine. He is a scientific reviewer at CNPq, FAPESP, FACEPE. Reviewer of several international journals including Heart, Annals of Internal Medicine, AIDS. Assistant to rector III at the University of São Paulo, from 25/01/2022. Science, research and activist disseminator in the fight against fake news about science on social media: 665 Tweets and 3,815 followers. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Our children |
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Diabetes mellitus (DM) is a complex disease that affects all organs of the body and whose prevalence is expanding in almost all countries of the world. The number of individuals with DM in Brazil increased from 2.7 to 11.7 million individuals from 1980 to 2014 (The Lancet 2016 387, 1513-1530). Regardless of the intrinsic mechanisms involved in the genesis of target organ involvement by di…
Dreams are potentially informative phenomena about pathological and emotional states. Therefore, it should be considered as a privileged source of information about the patient in situations of risk, trauma and recovery, important indicators of clinical-psychological evolution. In this project we will investigate inpatients diagnosed with acute coronary syndrome (ACS) to investigate the r…
Primary prevention is the main strategy to control the global burden of cardiovascular disease. In clinical practice, food restriction represents a valuable preventive resource. However, low adhesion rates and diet abandonment are considered important obstacles in treatment. Considering the discovery of new markers and mechanisms that relate food restriction and to all other cardiovascula…
Patients undergoing noncardiac surgery are at increased risk of cardiovascular complications. The development of methods that can accurately predict the occurrence of these events is of critical importance and large studies have been published with this purpose. Based on these studies, several algorithms have been proposed predict of cardiovascular events postoperatively. However, quantif…
(Only some records are available in English at this moment)
Cardiovascular disease is a major cause of morbidity and mortality in patients undergoing arterial vascular surgery. These patients have a high risk of postoperative cardiac complications, especially because of the high prevalence of atherosclerosis. It was identified that patients at high risk are more likely to develop Perioperative Myocardial Injury (PMI) an important complication afte…
Cardiovascular diseases are the main cause of morbidity and mortality in diabetic patients. A few years ago, new hypoglycemic drugs are required to undergo cardiovascular safety studies for their release. In 2015 EMPA-REG OUTCOME study, which has approved empagliflozin, a new inhibitor of the type 2 co-transporter for sodium gluconate, was the first study to provide evidence that an antid…
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing research grants |
| 13 / 9 | Completed research grants |
| 15 / 7 | Completed scholarships in Brazil |
| 29 / 17 | All research grants and scholarships |
| Associated processes | |